Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodolfo Carrillo Jimenez

Interventional Cardiology Delray Beach, FL Medical Doctor

NPI 1871513754 CMS profile 311357

5210 Linton Blvd Ste 301, Delray Beach, FL 33484

Open in the dashboard

General payments

$11,625

448 records reported · program years 2019–2025

Research payments

$50

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$372,498 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Rodolfo Carrillo Jimenez of Delray Beach, FL is reported in the CMS Open Payments database as having received $11,625 across 448 general payments and $50 in research payments paid to them. Separately, studies naming them as principal investigator received $372,498 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 62nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,772 37
2024 General $1,179 51
2023 General $1,249 57
2022 General $1,527 70
2022 Research $50 1
2021 General $1,840 82
2020 General $1,349 56
2019 General $2,709 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodolfo Carrillo Jimenez
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rodolfo Carrillo Jimenez were reported at $1,772. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rodolfo Carrillo Jimenez Interventional Cardiology median Middle half National median
2019 $2,709 $1,097 $329–$3,048 $163
2020 $1,349 $473 $161–$1,480 $114
2021 $1,840 $677 $233–$1,827 $132
2022 $1,527 $978 $333–$2,724 $149
2023 $1,249 $1,136 $382–$2,986 $160
2024 $1,179 $1,181 $395–$3,326 $164
2025 $1,772 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,421 102 payments
  2. Janssen Pharmaceuticals, Inc $1,210 81 payments
  3. Boston Scientific Corporation $858 29 payments
  4. AstraZeneca Pharmaceuticals LP $733 30 payments
  5. Novartis Pharmaceuticals Corporation $561 34 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $412 19 payments
  7. Kestra Medical Technology Services, Inc. $410 10 payments
  8. Merck Sharp & Dohme Corporation $313 14 payments
  9. HeartFlow, Inc. $312 5 payments
  10. Amgen Inc. $308 14 payments
  11. Other $3,088 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,411 443 payments
  2. Education $214 5 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,210 81 payments
  2. Confirm Rx Cardiac Arrhythmias and Heart Failure $519 17 payments
  3. FARXIGA $492 18 payments
  4. Confirm Rx Cardiac Rhythm Management $457 15 payments
  5. ENTRESTO $384 26 payments
  6. VERQUVO $382 17 payments
  7. JARDIANCE $344 16 payments
  8. Varithena Administration Pack $302 4 payments
  9. LifeVest $279 11 payments
  10. Repatha $269 12 payments
  11. Other $7,324 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $50 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,686

Median for Cardiology: 2,533

Drug cost

$1,246,186

Median for Cardiology: $485,213

Branded share of claims

31.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 379 $425,820
Xarelto Rivaroxaban Brand 287 $355,272
Entresto Sacubitril/Valsartan Brand 205 $234,642
Jardiance Empagliflozin Brand 64 $64,055
Brilinta Ticagrelor Brand 70 $48,897
Mounjaro Tirzepatide Brand 34 $38,016
Repatha Sureclick Evolocumab Brand 29 $26,175
Farxiga Dapagliflozin Propanediol Brand 22 $17,995
Metoprolol Succinate Generic 472 $4,120
Losartan Potassium Generic 404 $2,870

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$477,986

Of which drugs: $1,923

Medicare patients

1,218

Average age 80

Services billed

6,473

632 women, 586 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 58%
Atrial fibrillation 46%
Chronic kidney disease 46%
Diabetes 41%
Heart failure 39%
Depression 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dipyridamole, per 10 mg J1245 Office 130 624 $1,842
Injection, aminophyllin, up to 250 mg J0280 Office 14 14 $81

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $70
$70 — —
Repatha
  • Amgen Inc. $57
$57 29 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $42
$42 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $38
$38 287 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $37
$37 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

449 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record